Incyte shuffles pipeline priorities following FDA discussions

26 January 2022
lab_beaker_research_biotech_big

Delaware, USA-based Incyte (Nasdaq: INCY), a developer of novel therapies to address serious unmet medical need, has stopped working on the small molecule parsaclisib and the novel antibody MCLA-145.

The announcement, prompted by discussions with the US Food and Drug Administration over the regulatory pathway for parsaclisib, depressed shares in both Incyte and Innovent Biologics (HKEX: 01801), a Hong Kong-based firm which in-licensed certain Asian rights to the drug as part of a broader deal in December 2018.

Incyte is withdrawing a New Drug Application for parsaclisib in refractory follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology